Pancreatic Cancer Research

Clinical trialPhase 1Unknown

AMT-151 in Patients With Selected Advanced Solid Tumours

First-in-Human, Phase 1 Study of AMT-151, an Anti-Folate Receptor Alpha Antibody-Drug Conjugate, in Patients With Selected Advanced Solid Tumours

Outcome
Outcome unknown
Phase
Phase 1
Status
Unknown
Study type
Interventional
Start
25 January 2023
Listed end
30 October 2024
Enrollment
30 participants
Sites
9
Primary outcomes
Recommended Phase 2 Dose (RP2D); Maximum Tolerated Dose (MTD); Incidence of Adverse Events
Sponsor type
Industry
Results posted
No
Last update
19 October 2023

These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.

Ask this document

Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.

Try

Source text

Brief summary public domain (ClinicalTrials.gov)

This first-in-human study will evaluate the Maximum Tolerated Dose (MTD) / the Recommended Phase 2 Dose (RP2D), safety, tolerability, anti-tumor activity, pharmacokinetics, pharmacodynamics and immunogenicity of AMT-151, a novel antibody-drug conjugate against folate receptor alpha, in patients with selected advanced solid tumors.